ea0049gp190 | Pituitary & endocrine Tumours | ECE2017
Jorgensen Jens Otto
, Popovic-Brkic Vera
, Pournara Effie
, Pedersen Birgitte
, Chudecka Anita
, Strasburger Christian
Background: Long-term safety data (1998 to mid-2016) are reported for adult patients with GHD treated with GH (Norditropin® (somatropin), Novo Nordisk) as prescribed by treating physicians in the real-life clinical setting and enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), a non-interventional, multicentre study.Objective and hypotheses: To describe and report safety data and incidence rates (IRs) (...